# Arthrosi Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arthrosi-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.arthrosi.com
- Total disclosed funding: $69M
- Latest round: Series E (Jun 6, 2025)
- Investors on record: 9

## About

Founded in 2018 by its CEO Litain Yeh, and COO Shunqi Yan and based in California, US, Arthrosi Therapeutics operates as a biotechnology drugs developer.  In June 2025, Arthrosi Therapeutics, Inc. raised USD 60.87 million in series E funding led by Prime Eight Capital, with participation from CR Biotech, HighLight Capital, HM Venture Partners, and Reliant Technologies Inc. The series E funding values Arthrosi Therapeutics, Inc. at USD 217.11 million post-money.


The company provides biotechnology drugs for gout patients and chronic kidney disease. The company develops the first generation of urate inhibitor treatment for gout. The company's product includes AR882, which is a novel uric acid excretory agent in clinical development for the treatment of hyperuricemia in patients with gout, including those with chronic refractory gout.

The company plans to use the funding to finish the crucial development of Pozdeutinurad, a medication used to treat tophaceous and gout.

## Funding rounds

- Series E, Jun 6, 2025, $61M — Reliant Technologies Inc., HighLight Capital, HM Venture Partners, Prime Eight Capital
- Series C, May 20, 2020, $8.5M — HEDA Ventures, Changrong Capital, Fenghe Capital, LH Ventures, Viva Ventures Biotech

## Investors

- HEDA Ventures (https://capitalatlas.ai/funds/heda-ventures) — Series C
- Changrong Capital — Series C
- Fenghe Capital — Series C
- LH Ventures (https://capitalatlas.ai/funds/lh-ventures) — Series C
- Viva Ventures Biotech (https://capitalatlas.ai/funds/viva-ventures-biotech) — Series C
- Reliant Technologies Inc. — Series E
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series E
- HM Venture Partners — Series E
- Prime Eight Capital — Series E